Clinical Trial Review
December 2014 | Volume 13 | Issue 12 | Feature | 1501 | Copyright © 2014
Clinical Trial Review is a JDD department designed to provide physicians with information on drugs and devices undergoing clinical testing. It is our goal to inform the reader of the status of select drug and device studies relevant to the practice of dermatology before this information is available through standard channels. To participate in or learn more about these and additional trials, visit www.clinicaltrials.gov.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 17 Years of Age) With Mild to Moderate Plaque Psoriasis
Sponsored by Galderma, the objective of this study is to evaluate the safety and efficacy of up to 26 weeks of treatment with calcitriol 3 mcg/g ointment when used twice daily, without occlusion, to treat pediatric subjects (2 to 17 years of age) with mild to moderate plaque psoriasis.
The inclusion criteria for this study are male or female 2 to 17 years of age with a clinical diagnosis of stable mild to moderate plaque psoriasis.
The exclusion criteria are other forms of psoriasis hypercalcemia, past history of kidney stones, Vitamin D deficiency, or other concomitant dermatological disease.
Primary outcome measures are laboratory parameters related to calcium metabolism after 26 weeks of topical treatment with Calcitriol 3 mcg/g (Time Frame: week 26) and proportion of subjects with serum albumin-adjusted calcium higher than the upper normal limit and/or Parathyroid hormone (PTH) levels below the lower limit of normal, and incidence of urolithiasis.
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Sponsored by Novartis, This study is designed to evaluate the proportion of patients achieving reversal of chronic plaque psoriasis at week 4 and 12 following multiple doses of secukinumab administered subcutaneously (sc) compared to placebo. Starting from week 13, all patients will receive multiple doses of secukinumab up to week 52 to study long term effects of secukinumab. Clinical endpoints including biomarker assessments, PASI, IGA, and DLQI will be compared to better understand, why secukinumab may be effective in psoriasis patients. The primary outcome measure is for patients to achieve skin histology response after secukinumab treatment after 12 weeks of treatment.
Patients being tested have chronic plaque-type psoriasis diagnosed for at least 6 months, moderate to severe psoriasis as defined by: PASI score of ≥12, IGA score of ≥3, BSA (body surface area) affected by plaque-type psoriasis of ≥10%, and chronic plaque-type psoriasis considered inadequately controlled by: topical treatment and/or; phototherapy and/or previous systemic therapy.
MOLLUSCOM CONTA GIOSUM
A Dose Range-Finding Phase 2 Trial of a Botanical Drug for the Treatment of Molluscum Contagiosum in Pediatric Subjects
Sponsored by ViroXis Corporation, this trial will be a multi-center, double-blind, randomized, placebo-controlled safety and efficacy trial to evaluate the efficacy and safety of VIR003 treatment regimen when administered to pediatric subjects with molluscum contagiosum. Once subject eligibility is confirmed the subject will start the Treatment Period of the study. All subjects will receive one of three active treatments or placebo with the first dose applied at the day 0 study visit. Subjects will be instructed on how to apply the study medication twice a day for 60 days of treatment. Subjects will return to the clinic on study days, 7, 14, 30, 45, and 60 for routine evaluations and then on study day 90 for the final study visit.